Next Article in Journal / Special Issue
Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus Vectors
Previous Article in Journal
Immune-Mediated Therapies for Liver Cancer
Previous Article in Special Issue
Advances in Non-Viral DNA Vectors for Gene Therapy
Communication

Early Insights from Commercialization of Gene Therapies in Europe

1
Strategy Consulting, London SW15 2AW, UK
2
Kassenärztliche Vereinigung Westfalen Lippe, Dortmund 44141, Germany
*
Author to whom correspondence should be addressed.
Genes 2017, 8(2), 78; https://doi.org/10.3390/genes8020078
Received: 22 December 2016 / Accepted: 14 February 2017 / Published: 17 February 2017
(This article belongs to the Special Issue Gene Therapy)
Note: In lieu of an abstract, this is an excerpt from the first page.

After years of research and development, gene therapies are now becoming a commercial reality with several products approved by European regulatory authorities [...] View Full-Text
Keywords: gene therapies; payers; market access; Glybera; Strimvelis; Imlygic; reimbursement; commercialization gene therapies; payers; market access; Glybera; Strimvelis; Imlygic; reimbursement; commercialization
MDPI and ACS Style

Touchot, N.; Flume, M. Early Insights from Commercialization of Gene Therapies in Europe. Genes 2017, 8, 78. https://doi.org/10.3390/genes8020078

AMA Style

Touchot N, Flume M. Early Insights from Commercialization of Gene Therapies in Europe. Genes. 2017; 8(2):78. https://doi.org/10.3390/genes8020078

Chicago/Turabian Style

Touchot, Nicolas, and Mathias Flume. 2017. "Early Insights from Commercialization of Gene Therapies in Europe" Genes 8, no. 2: 78. https://doi.org/10.3390/genes8020078

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop